Actis to infuse over $700 mn to develop life sciences assets
Real Estate

Actis to infuse over $700 mn to develop life sciences assets

A global investor in sustainable infrastructure, Actis is planning to infuse over $700 million to build and develop assets under its platform focused on providing real estate to tenants in the life sciences and related sectors in the country.

Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts.

Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing.

The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune.

The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said.

He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market.

India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations.

More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented.

Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem.

Image Source

Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

A global investor in sustainable infrastructure, Actis is planning to infuse over $700 million to build and develop assets under its platform focused on providing real estate to tenants in the life sciences and related sectors in the country. Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts. Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing. The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune. The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said. He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market. India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations. More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented. Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem. Image Source Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

Next Story
Infrastructure Transport

Delhi Airport to Finalise 20-Year Master Plan

Delhi International Airport Ltd (DIAL) is finalising a 20-year master plan to guide long term infrastructure and operational development at Indira Gandhi International Airport, an official said. The operator expects the plan to reflect changes in the airline industry, shifts in the competitive landscape and evolving infrastructure requirements across terminals, airside and support services. The official said the document is likely to be ready in the next two to two-and-a-half months as the operator moves through planning stages. The plan will be prepared after consultations with airport users ..

Next Story
Real Estate

Aadhar Housing Finance Targets Rs 500 bn AUM By FY29

Aadhar Housing Finance has set a target to raise its asset under management to Rs 500 billion (bn) by the end of FY29, aiming to achieve this over the next three financial years through an 18-20 per cent loan growth trajectory. The firm focuses on the low-income segment with a ticket size of less than Rs 1.5 million (mn) and has relied on that segment to drive expansion. The company closed FY26 with an AUM of Rs 305.71 bn, reflecting the expansion in recent years, and it reported a net profit rise of 22 per cent to Rs 11.08 bn. Management indicated that gross non-performing assets stood at 1.0..

Next Story
Infrastructure Energy

Government to Launch Coal Gasification Urea Policy

The government will unveil a coal gasification based policy for urea production within one month, aiming to promote the use of domestic coal feedstock in synthetic fertiliser manufacture. The move seeks to enhance self reliance in fertiliser supply and to provide an alternative route to natural gas based synthesis. Officials said the policy will set out technical standards, permitting norms and incentives for projects that adopt coal gasification technology. It will aim to attract investments from both public sector undertakings and private manufacturers. The scheme will address logistical and..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement